Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management DOI Creative Commons
Jie Chen,

Na Ma,

Bo Chen

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 207, С. 104604 - 104604

Опубликована: Дек. 26, 2024

In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive transfer, have completed or are undergoing clinical trials for prostate cancer. Despite blockade's extraordinary effectiveness treating a variety of cancers, targeted treatment using the system is still its infancy. Multiple factors heterogeneity cancer, cold microenvironment, low level neoantigens, contribute poor response. Significant effort being devoted improving immune-based therapy. Recently, several key discoveries demonstrate that agents may be used promise better prognosis patients as part combination strategies with other targeting tumor-associated mechanism resistance. Here, this review comprehensively examines advancements exploring potential synergistic effects when combined modalities enhance efficacy.

Язык: Английский

Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer DOI Creative Commons
Fangming Wang, Nianzeng Xing, Jianxing Li

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Май 21, 2025

Background Castration-resistant prostate cancer (CRPC) has a poor prognosis and requires novel therapeutic approaches. Previously, we discovered that high dose of human peripheral blood-derived natural killer (PB-NK) cells can have antitumor effects against CRPC. However, whether antibodies prostate-specific membrane antigen (PSMA) direct adoptive NK to the tumor site therefore decrease cell dosage through antibody-dependent cellular cytotoxicity remains unknown. Methods were obtained from blood samples healthy donors. To engineer an anti-PSMA antibody (Ab), llama was immunized with PSMA protein, variable domains camelid heavy-chain (VHH) clones isolated using phage display. The VHH recombinantly fused Fc region produce Ab. In vitro , evaluated counting kit-8. Levels cytokines (PSA) determined ELISA. expression CD107a CD16 (the Ab Fc-receptor) in affinity detected flow cytometry. Antitumor patient-derived organoid (PDO) models 22RV1 tumor-bearing mice vivo . Results We constructed validated its toward antigen. is abundantly expressed PB-NK cells. significantly enhanced CRPC evidenced by increased killing rate, upregulation degranulation marker CD107a, secretion interferon-γ, decreased PSA levels. Furthermore, our combined treatment showed powerful PDO xenograft mouse models. Conclusion Combined improves efficacy promising approach treating clinical settings.

Язык: Английский

Процитировано

0
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy DOI Open Access
Whi‐An Kwon, Jae Young Joung

Cancers, Год журнала: 2025, Номер 17(11), С. 1820 - 1820

Опубликована: Май 29, 2025

Advanced prostate cancer (PCa) remains lethal despite standard therapies, and immune checkpoint inhibitors offer limited benefit in its “immune-cold” microenvironment. T-cell engagers (TCEs)—bispecific antibodies linking CD3 on T-cells to tumor-associated antigens (TAAs)—provide potent, MHC-independent cytotoxicity, overcoming a key resistance mechanism. While early PSMA-targeted TCEs established proof-of-concept, recent data, notably for six transmembrane epithelial antigen of the 1 (STEAP1)-targeting agents like Xaluritamig, demonstrate more substantial objective responses, highlighting progress through improved target selection molecular design. This review synthesizes evolving landscape targeting PSMA, STEAP1, DLL3 PCa. We critically evaluate emerging clinical evidence, arguing that realizing significant therapeutic potential requires challenges, including cytokine release syndrome (CRS), response durability, escape. contend future success hinges sophisticated engineering strategies (e.g., affinity tuning, masking, multispecific constructs) rationally designed combination therapies tailored disease-specific hurdles. Strategies toxicity mitigation, crucial role biomarker-driven patient selection, integration with existing treatments are also discussed. Accumulating evidence supports becoming new pillar advanced PCa, but achieving this demands sustained innovation focused optimizing efficacy safety. connects advancements realities imperatives.

Язык: Английский

Процитировано

0
Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook DOI Creative Commons
Wenhao Zhou, Xiaojun Lu, Feng Tian

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1384 - 1384

Опубликована: Дек. 9, 2024

Prostate cancer is a prevalent in elderly men, and immunotherapy has emerged as promising treatment approach recent years. The aim of to stimulate the body’s immune system target destroy cells. Cancer vaccines that are highly specific, safe, capable creating long-lasting responses key focus research. Despite progress clinical trials showing positive results, practical use still encounters various obstacles. complexity microenvironment variations systems individual patients have hindered research on prostate vaccines. This review examines history mechanisms vaccines, summarizes findings, explores future directions development

Язык: Английский

Процитировано

2
ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics DOI Creative Commons
Dhivya Sridaran, Nupam P. Mahajan

Trends in Pharmacological Sciences, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Activated CDC42-associated kinase 1 (ACK1), encoded by the TNK2 gene, is a cytoplasmic non-receptor tyrosine whose aberrant activation correlates positively with cancer severity. Recent research has revealed functional relevance of this oncokinase - it an epigenetic regulator that drives progression in multiple malignancies. Although ACK1 attractive target for therapeutic intervention, incomplete knowledge its diverse signaling mechanisms and lack specific inhibitors have challenged clinical success. We summarize recent breakthroughs understanding regulation cellular signaling, shed light on immunomodulatory role balancing T cell activation. provide comprehensive overview preclinical, proof-of-concept studies potent ACK1-targeting small-molecule are expected to enter trials patients.

Язык: Английский

Процитировано

2
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management DOI Creative Commons
Jie Chen,

Na Ma,

Bo Chen

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 207, С. 104604 - 104604

Опубликована: Дек. 26, 2024

In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive transfer, have completed or are undergoing clinical trials for prostate cancer. Despite blockade's extraordinary effectiveness treating a variety of cancers, targeted treatment using the system is still its infancy. Multiple factors heterogeneity cancer, cold microenvironment, low level neoantigens, contribute poor response. Significant effort being devoted improving immune-based therapy. Recently, several key discoveries demonstrate that agents may be used promise better prognosis patients as part combination strategies with other targeting tumor-associated mechanism resistance. Here, this review comprehensively examines advancements exploring potential synergistic effects when combined modalities enhance efficacy.

Язык: Английский

Процитировано

2